Physician profile
Henry M Patton
NPI 1396742144
$4,001.90
in general payments reported to CMS, 2019-2025
31 companies · $932 in 2025
The $932 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $222 · 2021: $72.83 · 2022: $244 · 2023: $803 · 2024: $945 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.88 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $669.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $460.72 | 2019-2025 | |
| Novo Nordisk INC | $440.28 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.84 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $331.49 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $177.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $132.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $130.15 | 2019-2025 | |
| Dexcom, INC. | $124.70 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $119.88 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $101.32 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $100.62 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $96.33 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $88.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.43 | 2024-2025 | Xifaxan, Trulance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $71.49 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $60.70 | 2025 | |
| Astellas Pharma US INC | $55.22 | 2023-2024 | Veozah |
| Abbvie INC. | $51.19 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $46.71 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $39.12 | 2024 | Voquezna |
| Boston Scientific Corporation | $38.44 | 2025 | General - Pain Management |
| Depuy Synthes Sales INC. | $36.35 | 2019 | |
| Exact Sciences Corporation | $27.99 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $25.00 | 2025 | Gemtesa |
| Corcept Therapeutics | $23.46 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.86 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $15.24 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.78 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.42 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.97 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.